Harry Welten
Director of Finance/CFO chez AFFIMED N.V.
Fortune : 58 300 $ au 31/03/2024
Profil
Harry Welten is currently the Chairman at Proteomedix AG, Chairman at Virometix AG, Director at BioSupport AG, Director at Kanyos Bio, Inc., Chief Financial Officer at Affimed NV, Member-Management Board at Horizon Therapeutics Switzerland GmbH, Member-Foundation Council at Fondation De l'Hôpital Barrie Memorial, Member-Foundation Council at HBM Fondation, and Member-Supervisory Board at Affimed GmbH.
He previously served as Chairman at Novaremed AG, Director at UBS Securities LLC, Director at Kuros Biosurgery Holding AG, Independent Director at DMS Imaging SA, Director at Synosia Therapeutics, Inc., Director at BiognoSYS AG, Director at Proteomedix AG, Director at Anokion SA, Director at Kuros Biosciences Ltd., Director at Kuros Biosciences AG, and Member-Management Board at Synosia Therapeutics AG.
He also held the position of Chief Financial Officer & Executive Vice President at Cytos Biotechnology AG and Chief Financial Officer & Senior Vice President at Arpida AG.
Mr. Welten completed his undergraduate and MBA degrees from The Trustees of Columbia University in The City of New York.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AFFIMED N.V.
0,07% | 15/03/2023 | 11 000 ( 0,07% ) | 58 300 $ | 31/03/2024 |
Postes actifs de Harry Welten
| Sociétés | Poste | Début |
|---|---|---|
| AFFIMED N.V. | Director of Finance/CFO | 31/12/2023 |
ProteoMediX AG
 ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | Chairman | 01/10/2014 |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Director/Board Member | - |
Virometix AG
 Virometix AG Pharmaceuticals: MajorHealth Technology Virometix AG is a Swiss biotechnology company that focuses on developing vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. Virometix is based in Schlieren, CH. The private company's mission is to address the growing medical need for vaccines to combat infectious and chronic human diseases. The company was founded by John Anthony Robinson, and the CEO is Anna Sumeray. | Chairman | - |
| HBM Fondation | Corporate Officer/Principal | - |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Director/Board Member | - |
Fondation De l'Hôpital Barrie Memorial
 Fondation De l'Hôpital Barrie Memorial Miscellaneous Commercial ServicesCommercial Services Fondation De l'Hôpital Barrie Memorial is a private company based in Ormstown, Canada. The Canadian company engages in raising funds to improve health care and services. | Corporate Officer/Principal | - |
| BioSupport AG | Director/Board Member | - |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Corporate Officer/Principal | - |
Anciens postes connus de Harry Welten
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Harry Welten
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AFFIMED N.V. | Health Technology |
| DMS IMAGING | Health Technology |
| KUROS BIOSCIENCES AG | Health Technology |
| Entreprise privées | 18 |
|---|---|
UBS Securities LLC
 UBS Securities LLC Investment Banks/BrokersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Finance |
Synosia Therapeutics AG
 Synosia Therapeutics AG Pharmaceuticals: MajorHealth Technology Synosia Therapeutics develops and intends to commercialize innovative products for unmet medical needs in psychiatry and neurology. The firm is working to extend the reach of marketed and clinical-stage compounds, acquired through strategic partnerships with Novartis, Roche and Syngenta, into new indications with significant potential. Founded in December 2005 and headquartered in Switzerland, Synosia is managed by a highly experienced management team with some 200 years of drug development experience. The company is backed by $62 million in funding from high-quality investors and has a rich portfolio of compounds. | Health Technology |
Cytos Biotechnology AG
 Cytos Biotechnology AG Miscellaneous Commercial ServicesCommercial Services Cytos Biotechnology AG engages in the development and commercialization of biopharmaceutical products. The company was founded by Wolfgang A. Renner, James E. Bailey and Hans M. Eppenberger in February 1995 and is headquartered in Zurich, Switzerland. | Commercial Services |
Kuros Biosurgery Holding AG
 Kuros Biosurgery Holding AG Miscellaneous Commercial ServicesCommercial Services Kuros Biosurgery Holding AG operated as a medical technology company. It engaged in the development of biologic and biomaterial-based product candidates for localized therapy in trauma, spine and wound care. The company was founded by Marion Bavand, Didier Cowling, Dominik Ellenrieder, and Jeffrey Hubbel on April 3, 2008 and was headquartered in Zurich, Switzerland. | Commercial Services |
Arpida AG
 Arpida AG BiotechnologyHealth Technology Arpida AG develops and discovers drugs for microbial resistance. The company's products include intravenous iclaprim, and antibiotics. The antibiotics provides resistance towards the methicillin-resistant Staphylococcus aureus (MRSA). The company also discovers an oral formulation of iclaprim. The company was founded by Dr. Dieter Gillessen, Bernhard Erni and Dr. Ivan Kompis in July 1997 and is headquartered in Reinach, Switzerland. | Health Technology |
Horizon Therapeutics Switzerland GmbH
Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Health Technology |
Synosia Therapeutics, Inc.
 Synosia Therapeutics, Inc. Medical SpecialtiesHealth Technology Synosia Therapeutics, Inc. used to develop products for unmet medical needs in psychiatry and neurology. The company was founded in December 2005 and was headquartered in San Francisco, CA. | Health Technology |
BiognoSYS AG
 BiognoSYS AG Packaged SoftwareTechnology Services BiognoSYS AG operates as a biotechnology company. Its products include iRT Kit, HRM Kit, Sample Prep Kit, PlasmaDive, Spectronaut and SpectroDive. The company was founded by Philipp M. Antoni, Johan Malmstroem and Oliver Rinner on September 3, 2008 and is headquartered in Schlieren, Switzerland. | Technology Services |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Health Technology |
ProteoMediX AG
ProteoMediX AG BiotechnologyHealth Technology ProteoMediX AG operates in the identification of novel biomarkers for the early detection of cancer and the personalized treatment. The firm products include Prostate cancer detection, stratification and prognosis. The company was founded by Ralph Schiess, Christian Br?hlmann and Wilhelm Krek in 2010 and is headquartered in Schlieren, Switzerland. | Health Technology |
| BioSupport AG | |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Health Services |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Fondation De l'Hôpital Barrie Memorial
Fondation De l'Hôpital Barrie Memorial Miscellaneous Commercial ServicesCommercial Services Fondation De l'Hôpital Barrie Memorial is a private company based in Ormstown, Canada. The Canadian company engages in raising funds to improve health care and services. | Commercial Services |
| HBM Fondation | |
Virometix AG
Virometix AG Pharmaceuticals: MajorHealth Technology Virometix AG is a Swiss biotechnology company that focuses on developing vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. Virometix is based in Schlieren, CH. The private company's mission is to address the growing medical need for vaccines to combat infectious and chronic human diseases. The company was founded by John Anthony Robinson, and the CEO is Anna Sumeray. | Health Technology |
Kuros Biosciences AG
 Kuros Biosciences AG Miscellaneous Commercial ServicesCommercial Services Kuros Biosciences AG is a Swiss company that specializes in developing innovative solutions for targeted and controlled bone healing. The private company is based in Schlieren, Switzerland. The company's mission is to eliminate non-unions and improve patient rehabilitation. | Commercial Services |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |
